Obama's stem cell policy is welcome change, but ethics are permanent feature of debate
By Jesse Reynolds,
The Jurist online
| 03. 18. 2009
President Obama's recent removal of his predecessor's stem cell policy is a welcome development. The Bush administration's restriction on the federal funding of human embryonic stem cell research was outdated and increasingly unpopular. While much of the media coverage of President Obama's announcement has focused on the research's potential and the political winners and losers, here are a few points that were overlooked:
For years, embryonic stem cell research in the US has been conducted in a federal regulatory vacuum, and the debate has been characterized by exaggerated rhetoric about imminent cures. Obama shifted the ground on both fronts. He ordered the National Institutes of Health(NIH) to draw up guidelines, which hopefully will be enforceable and apply to both publicly and privately funded research. The President also clearly called for a prohibition on reproductive cloning, which remains legal in the US and shares materials and methods with embryonic stem cell research. Furthermore, his language was optimistic but cautious; he noted that cures may not come in our lifetimes. This is a big change from advocates' over-the-top promises...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...